Free cash flow margin swung between -32.2% and 35.1% over the ten-quarter window, with a $293.1M net acquisition outflow in 2025Q4 indicating capital deployment has been directed primarily toward acquisitions rather than shareholder returns.
Supernus Pharmaceuticals, Inc. (SUPN) cash flow statement — 18-year operating, investing & financing cash flows
| Metric | TTM | Dec'25 | Dec'24 | Dec'23 | Dec'22 | Dec'21 | Dec'20 | Dec'19 | Dec'18 | Dec'17 | Dec'16 | Dec'15 | Dec'14 | Dec'13 | Dec'12 | Dec'11 | Dec'10 | Dec'09 | Dec'08 |
|---|
| Cash from Operations | 96M | -27M | 36M | -300M | -4M | 353M | -193M | 151M | 303M | 295M | 407M | 32.12M | 7.73M | -57.95M | -47.2M | -36.19M | -32.54M | 2.63M | -29.65M |
| Operating CF Margin % | - | -2.18% | 3.03% | -27.45% | -0.44% | 44.63% | -29.83% | 19.24% | 31.56% | 25.69% | 42.01% | 22.24% | 6.34% | -482.14% | -3189.12% | -4506.23% | -30701.89% | 6.95% | -333.58% |
| Operating CF Growth % | -4038.35% | -175% | 112% | -7400% | -101.13% | 282.9% | -227.81% | -50.17% | 2.71% | -27.52% | 1167% | 315.4% | 113.34% | -22.78% | -30.44% | -11.19% | -1335.54% | 108.88% | - |
| Net Income | 450M | 210M | 7M | -126M | -44M | 213M | -156M | 178M | 292M | 193M | 149M | 14.02M | 19.87M | -92.27M | -46.28M | -23.23M | -39.08M | 4.14M | -33.48M |
| Depreciation & Amortization | 13M | 20M | 28M | 15M | 16M | 22M | 26M | 28M | 16M | 13M | 14M | 921K | 928K | 742K | 871K | 879K | 1.19M | 1.07M | 1.11M |
| Stock-Based Compensation | 33M | 26M | 24M | 21M | 16M | 11M | 8M | 3M | 15M | 16M | 10M | 4.23M | 2.72M | 1.91M | 443K | -82K | 297K | 111K | 99K |
| Deferred Taxes | -3M | -46M | 7M | -64M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2.15M | -371K | 22.96M | 653K | -16.25M | -399K | -4.59M | 0 |
| Other Non-Cash Items | 37M | 20M | 16M | 151M | -110M | -66M | -52M | 21M | -49M | -68M | -104M | 748K | 2.09M | 3.03M | 330K | 2.3M | -408K | 382.45K | 179K |
| Working Capital Changes | -434M | -257M | -46M | -297M | 118M | 173M | -19M | -79M | 29M | 141M | 338M | 10.06M | -17.5M | 5.67M | -3.21M | 188K | 5.85M | 1.52M | 2.44M |
| Change in Receivables | 4M | 3M | -1M | -33M | -21M | -25M | 15M | 79M | -33M | -59M | -27M | -8.64M | -12.22M | -5.04M | -11K | -85K | 284K | -329K | -1.16M |
| Change in Inventory | 3M | 18M | -43M | -6M | -30M | -3M | -16M | 7M | -31M | -6M | 4M | 854K | -6.29M | -6M | -1.15M | 134K | 294K | -322K | 2.49M |
| Change in Payables | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2.06M | -1.28M | 8.49M | -1.1M | -1.1M | 5.21M | 1.81M | 1.09M |
| Cash from Investing | -65M | -66M | 69M | -95M | -222M | -14M | -4M | -2M | -4M | -43M | -35M | -36.23M | -4.89M | -12.11M | -48.96M | 33.9M | 25.82M | -28.39M | 15.48M |
| Capital Expenditures | -65M | -66M | -29M | -8M | -5M | -4M | -4M | -7M | -11M | -30M | -20M | -2.1M | -593K | -2.35M | -753K | -685K | -294K | -714K | -135K |
| CapEx % of Revenue | 4.73% | 5.33% | 2.44% | 0.73% | 0.55% | 0.51% | 0.62% | 0.89% | 1.15% | 2.61% | 2.06% | 1.46% | 0.49% | 19.56% | 50.88% | 85.31% | 277.36% | 1.88% | 1.52% |
| Acquisitions | 0 | 0 | 0 | -129M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 705K | 0 | 0 | 0 | 0 | 0 |
| Investments | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Other Investing | -1M | 0 | -2M | -42M | 1M | -10M | 0 | 5M | 7M | -13M | -15M | -8.51M | -4.5M | -705K | -48.21M | 25.61M | 0 | 0 | 0 |
| Cash from Financing | -171.25M | -30M | -102M | -64M | -101M | -94M | -10M | -13M | -237M | -84M | -147M | 1.87M | 570K | 62.74M | 87.92M | 27.09M | -944K | 4.28M | 64.46M |
| Debt Issued (Net) | 151.23M | -17M | 92M | -12M | -3M | 14M | -4M | -4M | -240M | -86M | -78M | 0 | 0 | 65.66M | -6.78M | 30M | 0 | 0 | 75M |
| Equity Issued (Net) | -325.46M | -14M | -192M | -52M | -98M | -100M | 1M | 0 | 3M | 2M | 0 | 1.87M | 571K | 0 | 100.73M | 29K | 4K | 20K | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -69M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Share Repurchases | -302.46M | -11M | -173M | -33M | -90M | -101M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Financing | 2.98M | 1M | -2M | 0 | 0 | -8M | -7M | -9M | 0 | 0 | 0 | 0 | -1K | -2.92M | -6.04M | -2.94M | -948K | 4.26M | -10.54M |
| Net Change in Cash | -139M | -124M | 3M | -458M | -328M | 244M | -202M | 136M | 61M | 171M | 225M | -2.24M | 3.42M | -7.32M | -8.24M | 24.8M | -7.67M | -21.47M | 50.29M |
| Free Cash Flow | 31M | -94M | 5M | -353M | -9M | 319M | -197M | 144M | 262M | 252M | 372M | 30.02M | 7.14M | -60.3M | -47.95M | -36.87M | -32.84M | 1.92M | -29.79M |
| FCF Margin % | 2.26% | -7.59% | 0.42% | -32.3% | -1% | 40.33% | -30.45% | 18.34% | 27.29% | 21.95% | 38.39% | 20.78% | 5.85% | -501.71% | -3240% | -4591.53% | -30979.25% | 5.06% | -335.1% |
| FCF Growth % | -76.15% | -1980% | 101.42% | -3822.22% | -102.82% | 261.93% | -236.81% | -45.04% | 3.97% | -32.26% | 1139.22% | 320.43% | 111.84% | -25.75% | -30.06% | -12.28% | -1810.31% | 106.45% | - |
| FCF per Share | 0.25 | -0.73 | 0.04 | -2.49 | -0.06 | 2.07 | -1.34 | 0.95 | 1.74 | 1.68 | 2.50 | 0.59 | 0.14 | -1.89 | -2.75 | -2.66 | -2.37 | 0.14 | -2.15 |
| FCF Conversion (FCF/Net Income) | 0.07x | -0.13x | 18.00x | 2.33x | 0.09x | 1.72x | 1.30x | 1.13x | 1.15x | 4.84x | 12.70x | 2.29x | 0.39x | 0.63x | 1.02x | -0.65x | 0.85x | 5.73x | 0.89x |
| Interest Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Taxes Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Quick answers to the most common questions about buying SUPN stock.
Supernus Pharmaceuticals, Inc. (SUPN) generated $-27.0M in net cash from operating activities in 2025. This reflects the cash generated directly from core business operations.
Supernus Pharmaceuticals, Inc. (SUPN) reported negative free cash flow of $94.0M in 2025, indicating capital requirements exceeded cash from operations.
Supernus Pharmaceuticals, Inc. (SUPN) spent $66.0M on capital expenditures in 2025. CapEx represents the cash invested in physical assets like property, plant, and equipment to maintain or grow the business.
In 2025, Supernus Pharmaceuticals, Inc. (SUPN) spent $11.0M on share repurchases. This shows the company's commitment to returning capital to its equity investors.
Key Metrics
Top Statement Risk
Volatile operating cash generation
Metrics are mathematically derived from official filings.
Net Income Diverges From Operating Cash
According to the supplied cash flow statements, SUPN's operating cash flow to net income ratio swung from 2.90 to -29.01 across recent quarters, indicating that reported earnings are a poor guide to actual cash generation in any single period.
The ratio's extreme dispersion suggests that quarterly net income is being driven by items such as non-cash charges, timing of revenue recognition, or non-operating gains rather than steady cash earnings. Where net income is negative but operating cash flow is positive, as in 2026Q1, working capital release or non-cash add-backs may be carrying the period, which warrants further investigation before treating either figure as representative. Investors should monitor whether conversion stabilizes over a full year rather than relying on individual quarters.
Free Cash Flow Lumpy Despite Recent Strength
Based on the reported figures, SUPN's free cash flow margin ranged from -32.2% to 35.1% over the ten-quarter window, with the most recent quarter at 23.3%, reflecting high volatility rather than a consistent upward trajectory.
The swing between deeply negative and strongly positive free cash flow suggests that the business's cash output is heavily dependent on the timing of collections and operating expense cycles. The 2026Q3 rebound to $83.0M appears encouraging, but a single strong quarter following multiple negative periods does not establish durable cash generation. Investors should monitor whether margins hold above 20% across consecutive quarters.
Working Capital Drives Quarterly Cash Variance
As reported in the cash flow statements, SUPN's working capital change moved from -$51.4M in 2025Q4 to +$21.8M in 2026Q1, a $73.2M swing that accounts for much of the period-to-period movement in operating cash flow.
The magnitude of working capital swings relative to operating cash flow suggests that receivables, inventory, or payables timing is a dominant driver of cash results rather than underlying operating performance. Large negative working capital draws in late 2025 followed by releases in early 2026 may reflect collection timing rather than structural change. Investors should monitor whether these reversals net out over a full cycle.
Acquisition Outflow Dominates Capital Use
According to the supplied filings, SUPN recorded a net acquisition outflow of $293.1M in 2025Q4 while paying no dividends and making negligible buybacks, indicating that capital deployment has been directed almost entirely toward acquisitions.
The absence of dividends and minimal repurchases suggests management has prioritized external growth over shareholder distributions during this period. The $293.1M outflow is large relative to the company's recent quarterly operating cash flow and may indicate reliance on balance sheet resources to fund growth. Investors should monitor the return on this acquisition spend against future cash flow generation.
Asset-Light Capital Intensity Persists
Based on reported figures, SUPN's capital expenditure remained below 0.6% of revenue in every quarter of the ten-quarter window, with depreciation and amortization consistently exceeding capex by a wide margin.
Capex intensity this low is characteristic of a business with limited physical asset requirements, so cash flow is less burdened by maintenance reinvestment. The persistent gap between D&A and capex suggests that the reported asset base is being amortized from prior acquisitions rather than replaced, which may flatter near-term free cash flow. Investors should monitor whether the amortization of acquired intangibles continues to depress reported earnings while leaving cash flow largely unaffected.
Quarterly Cash Strength May Be Flattering
According to the supplied cash flow data, SUPN's strong 2026Q3 free cash flow of $83.0M followed a -$5.4M quarter, so a single period of positive cash generation may overstate the durability of the recovery.
Working capital releases and non-cash add-backs such as D&A of $25.7M in 2026Q2 can lift operating cash flow in periods where underlying earnings remain weak, which may mask the operating volatility visible in the income statement. The 2026Q2 net loss of -$58.4M alongside positive D&A indicates that cash results are sensitive to accounting add-backs rather than sustained earnings power. Investors should monitor whether free cash flow remains positive once working capital effects normalize across a full year.